NorthWest Biotherapeutics Inc (NWBO)

[Lykiri]

Correction to: Lessons learned from phase 3 trials of immunotherapy for glioblastoma: Time for longitudinal sampling?

Neuro-Oncology, noad241, https://doi.org/10.1093/neuonc/noad241

Published: 18 December 2023

This is a correction to: Neuro-Oncology, noad211, https://doi.org/10.1093/neuonc/noad211

This is a correction to: Ethan Chen, Alexander L Ling, David A Reardon, E Antonio Chiocca, Lessons learned from phase 3 trials of immunotherapy for glioblastoma: Time for longitudinal sampling?, Neuro-Oncology, 2023, noad211, https://doi.org/10.1093/neuonc/noad211

In the originally published version of this manuscript, there is a factual mistake in the sentence:

In this manuscript, the data were reanalyzed and now the DCVax-L group exhibited a mOS of 19.3 months, almost 4 months lower than the one reported previously

The correct version should state:

In this manuscript, the data were reanalyzed and now the DCVax-L group exhibited a mOS of 19.3 months from randomization and 22.4 months from surgery.

This error has been corrected online.

https://academic.oup.com/neuro-oncology/advance-article/doi/10.1093/neuonc/noad241/7477448?login=false